AGÕæÈ˹ٷ½

STOCK TITAN

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Vera Therapeutics (Nasdaq: VERA) announced inducement grants to fifteen new employees under its Inducement Plan, approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The grants include non-qualified stock options to purchase 133,500 shares of Class A common stock at $24.00 per share and restricted stock units (RSUs) for 73,695 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest 25% annually over four years starting August 20, 2025.

Vera Therapeutics (Nasdaq: VERA) ha annunciato concessioni di incentivi a quindici nuovi dipendenti nell'ambito del suo Piano di Induzione, approvato dal Comitato per la Remunerazione in conformità con la Regola Nasdaq 5635(c)(4).

Le concessioni comprendono opzioni azionarie non qualificate per l'acquisto di 133.500 azioni di azioni ordinarie di Classe A al prezzo di 24,00 $ per azione e unità di azioni vincolate (RSU) per 73.695 azioni. Le opzioni azionarie matureranno in quattro anni, con il 25% che matura dopo un anno e il resto mensilmente nei successivi 36 mesi. Le RSU matureranno per il 25% ogni anno per quattro anni a partire dal 20 agosto 2025.

Vera Therapeutics (Nasdaq: VERA) anunció concesiones de incentivos a quince nuevos empleados bajo su Plan de Inducción, aprobado por el Comité de Compensación conforme a la Regla 5635(c)(4) de Nasdaq.

Las concesiones incluyen opciones sobre acciones no calificadas para comprar 133,500 acciones de acciones ordinarias Clase A a $24.00 por acción y unidades de acciones restringidas (RSU) por 73,695 acciones. Las opciones sobre acciones se consolidarán durante cuatro años, con un 25% consolidado después del primer año y el resto mensualmente durante los siguientes 36 meses. Las RSU se consolidarán un 25% anual durante cuatro años a partir del 20 de agosto de 2025.

Vera Therapeutics (나스ë‹�: VERA)ëŠ� 나스ë‹� ìƒìž¥ 규칙 5635(c)(4)ì—� ë”°ë¼ ë³´ìƒìœ„ì›íšŒê°€ 승ì¸í•� ìœ ì¸ ê³„íšì—� ë”°ë¼ 15ëª…ì˜ ì‹ ìž… ì§ì›ì—게 ìœ ì¸ ë³´ì¡°ê¸ˆì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.

보조금엵ç� 비ìžê²� 주ì‹ë§¤ìˆ˜ì„ íƒê¶�ì� í¬í•¨ë˜ì–´ 있으ë©�, 133,500ì£�ì� í´ëž˜ìŠ� A 보통주를 주당 $24.00ì—� 매수í•� ìˆ� 있는 권리와 73,695ì£�ì� 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ê°€ í¬í•¨ë©ë‹ˆë‹�. 주ì‹ë§¤ìˆ˜ì„ íƒê¶Œì€ 4ë…„ì— ê±¸ì³ ë² ìŠ¤íŒ…ë˜ë©�, 1ë…� í›� 25%ê°€ 베스팅ë˜ê³� 나머지ëŠ� 36개월 ë™ì•ˆ 매월 베스팅ë©ë‹ˆë‹¤. RSUëŠ� 2025ë…� 8ì›� 20ì¼ë¶€í„� 매년 25%ì”� 4ë…„ê°„ 베스팅ë©ë‹ˆë‹¤.

Vera Therapeutics (Nasdaq : VERA) a annoncé des attributions d'incitation à quinze nouveaux employés dans le cadre de son Plan d'Incitation, approuvé par le Comité de Rémunération conformément à la règle Nasdaq 5635(c)(4).

Les attributions comprennent des options d'achat d'actions non qualifiées pour acquérir 133 500 actions ordinaires de classe A au prix de 24,00 $ par action ainsi que des unités d'actions restreintes (RSU) pour 73 695 actions. Les options d'achat d'actions seront acquises sur quatre ans, avec 25 % acquis après un an et le reste mensuellement sur 36 mois. Les RSU seront acquises à hauteur de 25 % par an sur quatre ans à partir du 20 août 2025.

Vera Therapeutics (Nasdaq: VERA) gab Anreizzuteilungen an fünfzehn neue Mitarbeiter im Rahmen seines Anreizplans bekannt, der vom Vergütungsausschuss gemäß der Nasdaq-Listenregel 5635(c)(4) genehmigt wurde.

Die Zuteilungen umfassen nicht qualifizierte Aktienoptionen zum Kauf von 133.500 Aktien der Klasse A zu 24,00 $ pro Aktie sowie Restricted Stock Units (RSUs) ´Úü°ù 73.695 Aktien. Die Aktienoptionen werden über vier Jahre unverfallbar, wobei 25 % nach einem Jahr unverfallbar werden und der Rest monatlich über 36 Monate. Die RSUs werden ab dem 20. August 2025 jährlich zu 25 % über vier Jahre unverfallbar.

Positive
  • None.
Negative
  • None.

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees� employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on July 6, 2025 has an exercise price per share equal to $24.00, Vera’s closing trading price on July 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit .

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051


FAQ

What inducement grants did Vera Therapeutics (VERA) announce on July 10, 2025?

Vera announced stock options for 133,500 shares at $24.00 per share and RSUs for 73,695 shares granted to fifteen new employees.

What is the vesting schedule for VERA's new stock options granted on July 6, 2025?

The stock options vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly over 36 months.

How will the RSUs vest in Vera Therapeutics' July 2025 inducement grants?

The RSUs will vest over 4 years, with 25% of shares vesting annually on each anniversary of August 20, 2025.

What was the exercise price for VERA's stock options granted on July 6, 2025?

The stock options were granted with an exercise price of $24.00 per share, based on Vera's closing price on July 3, 2025.
Vera Therapeutics, Inc.

NASDAQ:VERA

VERA Rankings

VERA Latest News

VERA Latest SEC Filings

VERA Stock Data

1.51B
60.71M
7.1%
108.72%
12.23%
Biotechnology
Pharmaceutical Preparations
United States
BRISBANE